Journal
CELL METABOLISM
Volume 32, Issue 1, Pages 15-30Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2020.04.001
Keywords
-
Categories
Funding
- National Institutes of Health [P01AG021654]
- Nathan Shock Center of Excellence in the Basic Biology of Aging [P30AG038072]
- Paul F. Glenn Center for the Biology of Aging Research at the Albert Einstein College of Medicine
- Albert Einstein College of Medicine's Ph.D. in Clinical Investigation program
Ask authors/readers for more resources
Biological aging involves an interplay of conserved and targetable molecular mechanisms, summarized as the hallmarks of aging. Metformin, a biguanide that combats age-related disorders and improves health span, is the first drug to be tested for its age-targeting effects in the large clinical trial-TAME (targeting aging by metformin). This review focuses on metformin's mechanisms in attenuating hallmarks of aging and their interconnectivity, by improving nutrient sensing, enhancing autophagy and intercellular communication, protecting against macromolecular damage, delaying stem cell aging, modulating mitochondrial function, regulating transcription, and lowering telomere attrition and senescence. These characteristics make metformin an attractive gerotherapeutic to translate to human trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available